T. Rowe Price Associates’s IGM Biosciences IGMS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$40K Sell
35,210
-7,654
-18% -$8.7K ﹤0.01% 3022
2025
Q1
$50K Sell
42,864
-3,526,135
-99% -$4.11M ﹤0.01% 2932
2024
Q4
$21.8M Sell
3,568,999
-445,260
-11% -$2.72M ﹤0.01% 972
2024
Q3
$66.4M Sell
4,014,259
-60,832
-1% -$1.01M 0.01% 671
2024
Q2
$28M Buy
4,075,091
+187,068
+5% +$1.29M ﹤0.01% 868
2024
Q1
$37.5M Buy
3,888,023
+628,001
+19% +$6.06M ﹤0.01% 798
2023
Q4
$27.1M Buy
3,260,022
+17,307
+0.5% +$144K ﹤0.01% 868
2023
Q3
$27.1M Buy
3,242,715
+11,845
+0.4% +$98.9K ﹤0.01% 843
2023
Q2
$29.8M Buy
3,230,870
+1,109,995
+52% +$10.2M ﹤0.01% 833
2023
Q1
$29.1M Sell
2,120,875
-85,532
-4% -$1.18M ﹤0.01% 824
2022
Q4
$37.5M Sell
2,206,407
-11,359
-0.5% -$193K 0.01% 738
2022
Q3
$50.4M Sell
2,217,766
-405,107
-15% -$9.21M 0.01% 641
2022
Q2
$47.3M Buy
2,622,873
+376,832
+17% +$6.79M 0.01% 892
2022
Q1
$60M Sell
2,246,041
-125,234
-5% -$3.35M 0.01% 907
2021
Q4
$69.5M Buy
2,371,275
+13,811
+0.6% +$405K 0.01% 886
2021
Q3
$155M Buy
2,357,464
+371,393
+19% +$24.4M 0.01% 631
2021
Q2
$165M Buy
1,986,071
+189,760
+11% +$15.8M 0.02% 621
2021
Q1
$138M Buy
1,796,311
+467,527
+35% +$35.9M 0.01% 671
2020
Q4
$117M Buy
1,328,784
+460,573
+53% +$40.7M 0.01% 674
2020
Q3
$64.1M Sell
868,211
-39,017
-4% -$2.88M 0.01% 791
2020
Q2
$66.2M Buy
907,228
+88,926
+11% +$6.49M 0.01% 757
2020
Q1
$45.9M Sell
818,302
-99,219
-11% -$5.57M 0.01% 811
2019
Q4
$35M Buy
917,521
+102,242
+13% +$3.9M ﹤0.01% 1021
2019
Q3
$14.5M Buy
+815,279
New +$14.5M ﹤0.01% 1232